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OBJECTIVE—The ubiquitin-proteasome system is the main
degradation machinery for intracellularly altered proteins. Hy-
perglycemia has been shown to increase intracellular levels of
the reactive dicarbonyl methylglyoxal (MGO) in cells damaged
by diabetes, resulting in modiﬁcation of proteins and alterations
of their function. In this study, the inﬂuence of MGO-derived
advanced glycation end product (AGE) formation on the activity
of the proteasome was investigated in vitro and in vivo.
RESEARCH DESIGN AND METHODS—MGO-derived AGE
modiﬁcation of proteasome subunits was analyzed by mass
spectrometry, immunoprecipitation, and Western blots. Protea-
some activity was analyzed using proteasome-speciﬁc ﬂuoro-
genic substrates. Experimental models included bovine retinal
endothelial cells, diabetic Ins2
Akita mice, glyoxalase 1 (GLO1)
knockdown mice, and streptozotocin (STZ)-injected diabetic
mice.
RESULTS—In vitro incubation with MGO caused adduct forma-
tion on several 20S proteasomal subunit proteins. In cultured
endothelial cells, the expression level of the catalytic 20S pro-
teasome subunit was not altered but proteasomal chymotrypsin-
like activity was signiﬁcantly reduced. In contrast, levels of
regulatory 19S proteasomal proteins were decreased. In diabetic
Ins2
Akita, STZ diabetic, and nondiabetic and diabetic G101
knockdown mice, chymotrypsin-like activity was also reduced
and MGO modiﬁcation of the 20S-2 subunit was increased.
CONCLUSIONS—Hyperglycemia-induced formation of MGO
covalently modiﬁes the 20S proteasome, decreasing its activity in
the diabetic kidney and reducing the polyubiquitin receptor
19S-S5a. The results indicate a new link between hyperglycemia
and impairment of cell functions. Diabetes 59:670–678, 2010
C
hronic hyperglycemia in diabetic patients is
characterized by increased intracellular glucose
concentration in cells damaged by diabetes
complications, such as endothelial cells. Intra-
cellular hyperglycemia activates four major pathways im-
plicated in the pathogenesis of diabetes complications: the
hexosamine and polyol pathways, protein kinase C iso-
forms, and formation of the reactive carbonyl compounds
methylglyoxal (MGO) and glyoxal (1). These reactive
carbonyl compounds form covalent adducts with particu-
lar lysine and arginine residues in proteins, altering their
function (2,3). MGO is the major source of intracellular
advanced glycation end products (AGEs) (4). MGO is
metabolized by glyoxalase (GLO)1 and -2 to the end
product D-lactate. This system efﬁciently detoxiﬁes MGO
and its two-carbon analog glyoxal. GLO1 deﬁciency is
associated with high levels of intracellular AGE (5). MGO-
derived AGEs, which are particularly abundant in vascular
tissue, are thought to contribute to the observed vascu-
lopathies in late complications of diabetes. In particular,
these pathological conditions are associated with chron-
ic inﬂammation, atherosclerosis, and diabetic nephrop-
athy (6).
Several studies have reported that intracellular protein
glycation by MGO caused pathological changes in partic-
ular proteins (7–10). However, the possibility that MGO
modiﬁes protein subunits of the proteasome has not yet
been examined. The ubiquitin-proteasome system is re-
sponsible for the protein quality control in a given cell in
general through degradation or removal of misfolded or
damaged proteins that would adversely affect cell function
(11,12). Damaged or modiﬁed intracellular proteins be-
come targeted for proteolysis via Lys-48–connected poly-
ubiquitin chains followed by degradation in the 26S pro-
teasome. The 26S proteasome itself is comprised of two
main multiprotein components: the 20S core proteasome
containing the proteolytic activities and the 19S regulatory
complex. The 19S regulator complex binds ubiquitinated
proteins via the ubiquitin-interacting motifs of the S5a-
subunit (Rpn10), unfolds them, and directs them into the
20S core proteasome for subsequent degradation (13–15).
The 20S core complex contains three proteolytic activities:
a trypsin-, a chymotrypsin- and a peptidyl-glutamyl
(caspase)–like activity. As a protection mechanism against
damaged and aggregated proteins, the proteasome rapidly
eliminates oxidized, damaged proteins. Oxidative stress is
known to upregulate the ubiquitin-proteasome machinery
(16,17).
We hypothesized that MGO induced by chronic hyper-
glycemia could modify the proteasome and thereby impair
proteasome function. Thus, the inﬂuence of MGO modiﬁ-
cation on proteasome function was studied in vascular
endothelial cells, diabetic Ins2
Akita mice, streptozotocin
(STZ)-injected diabetic mice, nondiabetic GLO1-knock-
down mice, and STZ diabetic/GLO1-knockdown mice. Our
results indicate that hyperglycemia-induced MGO forma-
tion causes covalent modiﬁcation of the proteasome,
which results in decreased chymotrypsin-like proteasome
activity and reduced levels of the polyubiquitin receptor
19S-S5a.
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All chemicals and materials were purchased from Calbiochem (EMD Bio-
sciences, San Diego, CA) unless otherwise stated. Ins2
Akita mice and C57BL/6
wild-type mice were purchased from The Jackson Laboratories (Bar Habor,
ME). Six-month-old male Akita mice were killed and organs were removed in
accordance with the guidelines of the ethics committee of the University of
Heidelberg, School of Medicine Mannheim, and the procedures were approved
by local and national authorities. GLO1-knockdown mice on a C57/B6
background were created as previously described (18). In brief, short oligo-
nucleotides with a target sequence to mouse glo1 in a hairpin sequence were
subcloned into a lentiviral vector. The recombined plasmids were used to
generate lentiviral particles. shRNA lentivirus was injected into the peri-
vitelline space of single-cell C57/B6 mouse embryos. After incubation for 4–6 h,
embryos were implanted into pseudopregnant females and were carried to
term. Mice whose genome contained a single copy of the insert were identiﬁed
by Southern blotting and used to establish founder lines. glo1 mRNA and
protein levels were determined by quantitative PCR and Western blot analysis
and further conﬁrmed by measurement of GLO activity. Heterozygous off-
spring of the founder had a 45–65% decrease in tissue GLO1 activity, and these
mice were used in all experiments.
Insulin deﬁciency in GLO1-knockdown and wild-type mice was induced by
STZ injection. In brief, 7-week-old mice were rendered diabetic via intraperi-
toneal injections of 50 mg  kg
1  day
1 STZ (MP Biomedicals, Eschwege,
Germany). Mice developed hyperglycemia after 10–12 weeks, with reduced
insulin levels and increased glucose levels. Eight-month-old GLO1-knockdown
male mice were killed and organs removed in accordance with the guidelines
of the institutional animal care and use committee of the Albert Einstein
College of Medicine, New York, New York.
Cell culture. Human endothelial cell line EA-hy.926 and bovine retinal
endothelial cells were kindly provided by Dr. Sigrid Zink (Diabetes Research
Institute, University of Du ¨sseldorf, Germany). Cells were cultured at 37°C in
a5 %C O 2 atmosphere with a minimal volume of Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% (vol/vol) FBS; 100 units/ml penicillin; 100
g/ml streptomycin; and, for EA-hy.926 cells, additionally with 100 mol/l
hypoxanthine, 0.4 mol/l aminopterin, and 16 mol/l thymidine (HAT) ob-
tained from Sigma-Aldrich (Saint Louis, MO). All culture media were from
Gibco-Invitrogen (Carlsberg, CA). Cells were cultured in 5.5 mmol/l and 30
mmol/l glucose or mannitol for 14 days prior to analysis. Culture medium was
changed daily.
AGE preparation. AGE-BSA was prepared as previously described (19).
Brieﬂy, 12 mg/ml BSA was incubated with 250 mmol/l glucose and 50 mmol/l
sodium phosphate buffer, pH 7.4, for 6 weeks at 37°C under sterile conditions
and dialyzed against in sodium phosphate buffer, pH 7.4. Preparations of
differently modiﬁed forms of AGE-BSA were prepared by incubation with
MGO as previously described (19). Brieﬂy, 12 mg/ml BSA was incubated in
sodium phosphate buffer, pH 7.4, in the presence of 1 mmol/l MGO for 1–6
days at 50°C.
20S proteasome puriﬁcation. The 20S proteasome was puriﬁed from
EA-hy.926 cell extract–essentially as previously described but with some
modiﬁcations (20–22). Brieﬂy, proteasomes were eluted from DEAE-Sephacel
(GE, Waukesha, WI) with 500 mmol/l KCl and then further puriﬁed by ﬁltration
and ultracentrifugation in a sucrose gradient for 16 h at 100,000g. Fractions
containing 20S proteasomes were pooled and concentrated by ﬁltration and
chromatographed on a Mono-Q column HR5/5 (GE) with a 80–500 mmol/l KCl
gradient. All proteasome preparations were tested for proteasome activity as
described below and analyzed by SDS-PAGE.
Proteasome activity assay. Tissue homogenates and cells were lysed using
lysis buffer containing 25 mmol/l Tris-HCl, pH 7.5; 100 mmol/l KCl; 1 mmol/l
EDTA; 0.1% (vol/vol) Triton X-100; 1 mmol/l phenylmethane sulfonylﬂuoride;
and protease inhibitor cocktail (Complete; Roche Diagnostics, Mannheim,
Germany). Tissue or cells were homogenized with liquid nitrogen and a
mortar. Protein concentration was determined by the BCA protein assay
(Pierce, Rockford, IL). Thirty-microgram cells or tissue lysate was suspended
in 25 mmol/l Tris-HCl, pH 7.4; 1 mmol/l dithiothreitol; and 20 mmol/l KCl and
tested for proteasome activity in the absence or presence of 25 mol/l
proteasome inhibitor MG-132 with 100 mol/l each of ﬂuorogenic substrates
(activityproteasome  activitytotal  activityinhibitor): Z-Leu-Leu-Glu-7-amino-4-
methylcoumarin (AMC) for caspase-like, Succ-Leu-Leu-Val-Tyr-AMC for chy-
motrypsin-like, and Boc-Leu-Ser-Thr-Arg-AMC (Sigma-Aldrich) for trypsin-like
activity. Experiments were performed for3ha t37°C in microtiter plates using
a FLx800 microplate ﬂuorescence reader (ex., 380 nm; em., 460 nm). Vmax of
proteasomal activity (activitytotal  activityinhibitor) was determined by KC4
software (BIO-TEK, Bad Friedrichshall, Germany).
20S proteasome inhibition assay. Twenty-ﬁve micrograms of puriﬁed 20S
proteasomes were preincubated with 5 g AGE-BSA or 250 mol/l MGO,
glyoxal, or glyceraldehyde for 30 min at 4°C before the 20S proteasome
activity was measured as described above.
Western blot analysis. Thirty micrograms of total cell lysate was resolved by
SDS-PAGE on 10% gel and blotted onto a polyvinylidine ﬂuoride (PVDF)
membrane. Polyclonal rabbit anti-20S proteasome 4-subunit antibody (Cal-
biochem), polyclonal rabbit anti-19S antibody from Abcam (Cambridge, MA),
and polyclonal rabbit anti-ubiquitin antibody from Sanra Cruz (Santa Cruz,
CA) were used for detection. The membrane was stripped and reprobed with
anti–-actin antibody clone AC-74 (Sigma-Aldrich).
Immunoprecipitation. The lysates from mice tissues were precleared by
preimmune IgG plus protein A agarose beads for 2 h, and the supernatants
were immunoprecipitated by the indicated antibodies and a 50% slurry of
protein A agarose beads overnight at 4°C. After a washing with buffer
containing 50 mmol/l Tris, pH 7.5; 150 mmol/l NaCl; 1% NP-40; and 0.5%
deoxycholate with protease inhibitors, proteins were released and the 40-g
proteins were run in NUPAGE 4–12% Bis-Tris gels (Invitrogen) and then
transferred to PVDF membranes, then blotted by primary antibodies, and then
simultaneously incubated with the differentially labeled species-speciﬁc sec-
ondary antibodies: anti-rabbit (or anti-goat) IRDye 800CW (green) and anti-
mouse ALEXA680 (red). Membranes were scanned and quantiﬁed by the
ODYSSEY infrared imaging system (LI-COR). Antibody for 19S-S5a was
obtained from Abcam, and antibodies for 20S proteasome 1, 2, and 5 were
obtained from Santa Cruz Biotech. Antibody for speciﬁc ubiquitin-Lys48 chain
was obtained from Millipore (Bedford, MA).
Matrix-assisted laser desorption/ionization–time of ﬂight mass spectometry.
Puriﬁed 20S proteasome was short-term modiﬁed (30 min) with MGO, puriﬁed
by SDS-PAGE, and stained with coomassie, and protein bands were exercised
and digested with trypsin at 37°C overnight. Matrix-assisted laser desorption/
ionization–time of ﬂight mass spectometry (MALDI-TOF-MS) analysis was
performed as previously described (23). Brieﬂy, samples were extracted with
1% triﬂuoroacetic acid solution and mixed on target with 2.4-dihydroxy
benzoic acid/methylenbisphosphonic acid (each 5 mg/ml in water), air-dried,
and analyzed by a MALDI-TOF-MS (Ultraﬂex I; Bruker Daltonik, Bremen,
Germany).
Statistics. All data are expressed as means  SD (n  3) unless otherwise
indicated. Experimental conditions were compared with Student’s t test for
single measurements; those containing multiple comparisons were analyzed
using ANOVA. Differences were statistically signiﬁcant at P  0.05.
RESULTS
High glucose causes decreased proteasomal chymo-
trypsin-like activity. To investigate proteasomal activity
under hyperglycemic conditions, endothelial cells were
incubated with high (30 mmol/l) or low (5.5 mmol/l)
glucose for 14 days and proteasome activity was exam-
ined. While proteasomal trypsin-like and caspase-like ac-
tivities in cells incubated with high-glucose medium were
found to be unaltered (Fig. 1A and B), the chymotrypsin-
like proteasomal activity was signiﬁcantly reduced both in
macro- and microvascular endothelial cells (Fig. 1C).
Western blots showed that the expression level of 20S
proteasome subunits was not altered. Interestingly, the
expression level of the 19S regulatory complex was down-
regulated after incubation with high glucose (Fig. 1D).
Glycated albumin does not affect proteasomal activ-
ity in vitro. To determine whether MGO-AGE affects
proteasome activity, an in vitro digestion of MGO-modiﬁed
BSA by puriﬁed 20S proteasome was performed. Protea-
somes were incubated with increasing doses of glycated
AGE-BSA (0–33%) followed by analysis of proteasomal
activities. These were not altered by MGO-modiﬁed BSA at
any of the concentrations tested (Fig. 2). These results
indicate that MGO-modiﬁed substrates do not inﬂuence
proteasomal activity.
Glucose-derived carbonyl compounds inhibit the pro-
teasomal chymotrypsin-like activity in vitro. To study
the inﬂuence of glucose-derived reactive carbonyl com-
pounds on proteasome activities, isolated 20S proteasome
was incubated with 250 mol/l MGO, glyoxal, or glyceral-
dehyde for 30 min prior to activity testing. Short-term
M.A. QUEISSER AND ASSOCIATES
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strong inhibition of chymotrypsin-like activity but no
inﬂuence on the trypsin- or caspase-like activities of the
20S proteasome (Fig. 3A–C). Similarly, endothelial cells
incubated with 500 mol/l MGO, glyoxal, or glyceralde-
hyde for 12 h exhibited reduced chymotrypsin-like protea-
somal activity, but no change in the other proteasome
activities occurred (Fig. 4A–C). Furthermore, increased
accumulation of ubiquitinated proteins was observed in
endothelial cells exposed to reactive carbonyl compounds
(Fig. 4D).
To investigate the potential mechanism of proteasome
inhibition, puriﬁed 20S proteasomes were incubated with
MGO for 30 min in vitro, puriﬁed by SDS-PAGE, and
analyzed by mass spectrometry. The data demonstrated
primary MGO modiﬁcation of the catalytic proteasome
2-, 4-, and 5-subunits, resulting in the formation of
methylimidazolone [N-acetyl-N-(5-hydro-5-methyl)-4-imi-
dazolone], carboxyethyl-lysine, and argpyrimidine. In con-
trast, modiﬁcations in the -subunits could not be
detected (Table 1). These results suggest that endog-
enously produced reactive carbonyl compounds might be
responsible for the reduction of chymotrypsin-like activity
via modiﬁcation of speciﬁc -subunits.
Diabetic Ins2
Akita mice exhibit reduced proteasomal
activity. For analysis of the effect of hyperglycemia on
proteasomal activity in vivo, 6-month-old diabetic Ins2
Akita
mice (n  6), a model for type 1 diabetes that also
manifests IgA nephropathy, were killed and tissue homog-
enates were subjected to proteasome analysis (Fig. 5).
Trypsin- and caspase-like activities were not altered in
tissues from aorta and the heart (Fig. 5A and B), whereas
chymotrypsin-like activity was greatly reduced in kidney
and to a smaller extent in aorta of diabetic animals in
comparison with wild-type controls (Fig. 5C). Surprisingly,
all three proteasomal activities were reduced in the kid-
ney. The heart showed no signiﬁcant changes in general,
indicating that heart proteasomes were more resistant to
hyperglycemia. Western blot analysis revealed that the
protein-expression level of the catalytic 20S core protea-
some in tissue samples did not signiﬁcantly differ between
diabetic and nondiabetic animals (Fig. 5D and E). These
data indicate that proteasomal activity is impaired in
diabetic animals without affecting the protein levels of the
20S proteasome.
Nondiabetic GLO1-knockdown mice and STZ diabetic
mice demonstrate increased 20S MGO modiﬁcation
resulting in impaired proteasomal activity. To test the
hypothesis that reactive carbonyl compounds, especially
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FIG. 1. Proteasome activity in endothelial cells under chronic hyper-
glycemia. Proteasome activity and 20S proteasome expression levels
were analyzed in immortalized human endothelial Eahy.926 cells and in
primary bovine retinal endothelial cells (BRECs) following incubation
with low- and high-glucose medium for 14 days. Proteasomal trypsin-
like (A) and caspase-like (B) activities following incubation with
high-glucose medium were not signiﬁcantly changed in comparison
with those following low-glucose medium, whereas the proteasomal
chymotrypsin-like activity was signiﬁcantly reduced (C). The level of
the catalytic 20S proteasome remained constant, while the 19S regu-
latory complex expression was decreased, as shown by Western blot
(D). Data represent means  SD from at least ﬁve separate experi-
ments. *P < 0.05. RFU, relative ﬂuorescence unit.
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FIG. 2. Resistance of glycated albumin against proteasomal degrada-
tion in vitro. AGE-BSA (10 g) was incubated with isolated 20S
proteasome to examine the inﬂuence on proteasomal activity. The
degree in carboxy-methyl-lysine modiﬁcation of BSA (as demonstrated
by Western blotting) did not signiﬁcantly affect the chymotrypsin-like
activity of the 20S proteasome. Ponceau S staining is shown as a
loading control. Data represent means  SD from at least three
separate experiments. RFU, relative ﬂuorescence unit.
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nondiabetic GLO1 knockdown mice and STZ diabetic/
GLO1-knockdown mice were analyzed for MGO-modiﬁed
proteins and proteasome activity (Fig. 6). Nondiabetic
GLO1-knockdown mice exhibited a twofold increase in
MGO-hydroimidazolone staining; the same level of in-
crease was seen in STZ diabetic mice. STZ diabetic GLO1-
knockdown mice had a threefold increase compared with
nondiabetic wild-type mice–consistent with an additive
effect of a diabetes-induced increased MGO production
and a knockdown-induced decrease in MGO degradation
by GLO1 (Fig. 6A). In addition, GLO1-knockdown mice
had an increase in speciﬁc Ub-Lys48 staining and a
more dramatic increase was seen in STZ diabetic GLO1-
knockdown mice, indicating that proteasome-speciﬁc
polyubiquitinated proteins are accumulating in diabetic
mice (Fig. 6B). Furthermore, chymotrypsin-like activity in
kidney homogenates of GLO1-knockdown mice and STZ-
injected mice was signiﬁcantly decreased (Fig. 6C).
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FIG. 3. Inhibition of proteasomal chymotrypsin-like activity in vitro by
reactive carbonyl compounds. Reactive carbonyl compounds were in-
cubated with the 20S proteasome and the enzymatic activities deter-
mined. Trypsin-like (A) and caspase-like (B) activities were not
signiﬁcantly changed, whereas the chymotrypsin-like activity was sig-
niﬁcantly reduced (C). Data represent means  SD from at least three
separate experiments. *P < 0.01. GA, glyceraldehyde; GO, glyoxal;
RFU, relative ﬂuorescence unit.
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FIG. 4. Inhibition of proteasomal chymotrypsin-like activity in endo-
thelial cells and accumulation of ubiquitinated proteins. Immortalized
human endothelial Eahy.926 cells and primary bovine retinal endothe-
lial cells were each incubated for 12 h with 500 mol/l reactive carbonyl
compounds. Trypsin-like (A) and caspase-like (B) activities were not
changed, whereas the chymotrypsin-like activity was signiﬁcantly
reduced after incubation with each of the three reactive carbonyl
compounds (C). Incubation with reactive carbonyl compounds ex-
hibited accumulation of ubiquitinated proteins in a dose-dependent
manner (D). Data represent means  SD from at least three
separate experiments. *P < 0.05. GA, glyceraldehyde; GO, glyoxal;
RFU, relative ﬂuorescence unit.
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subunit 19S-S5a was assessed. 19S-S5a protein level was
decreased more than 50% in GLO1-knockdown and STZ
diabetic mice, respectively (Fig. 7A). We then assessed
MGO modiﬁcation of 20S proteasome by performing im-
munoprecipitation of speciﬁc 20S proteasomal compo-
nents, which were then immunoblotted for MGO
modiﬁcation. There was no difference in protein amount of
these subunits in kidney lysates for wild-type, GLO1-
knockdown, STZ diabetic, or STZ diabetic/GLO1-knock-
down mice. However, there was a twofold increase in
MGO modiﬁcation of the 20S 2-subunit in lysates from
nondiabetic GLO1-knockdown mice and a two- to ﬁvefold
increase in lysates from STZ diabetic and STZ diabetic/
GLO1-knockdown mice (Fig. 7B). This ﬁnding conﬁrms in
vivo our observation (Table 1) that the 20S proteasome
2-subunit is modiﬁed by methylimidazolone after incuba-
tion with MGO in vitro. However, at MGO levels found in
vivo, there was no detectable modiﬁcation of the
5-subunit.
DISCUSSION
An undisturbed function of the ubiquitin-proteasome sys-
tem is essential for cellular processes—such as cell-cycle
progression, signal transduction, and antigen processing—
to occur normally (20,21,24). Different pathologies can
inﬂuence cellular signal transduction systems and may
also affect the functional activities of the proteasome. The
inﬂuence on the ubiquitin-proteasome system of hypergly-
cemia associated with diabetes in this regard has yielded
seemingly contradictory results. Several reports have dem-
onstrated that high glucose levels lead to an acceleration
of proteasomal activity with the consequences of muscle
wasting and sustained nuclear factor-B activation (19,25–
27), while other reports have shown impaired proteasome
function in diabetes and arteriosclerosis (28,29). Previous
reports demonstrated that AGEs inﬂuence proteolytic
degradation through decreased cathepsin activity, suggest-
ing that AGEs affect proteolysis (30,31).
Here, we demonstrate that proteasome activity is de-
creased in vitro and in vivo under conditions of chronic
hyperglycemia. Incubation of endothelial cells with high
glucose (14 days) led to reduction of the proteasomal
chymotrypsin-like activity in vitro. This defect was repli-
cated by exposure of the cells to the dicarbonyl MGO,
which covalently modiﬁed 20S proteasome subunits. Sim-
ilar, results were obtained using kidney from nondiabetic
GLO1-knockdown mice, indicating that increased MGO
alone is sufﬁcient to cause proteasome dysfunction. Like-
wise, results were obtained from kidneys of diabetic mice,
demonstrating that the increased levels of MGO induced
by diabetic hyperglycemia are sufﬁcient to cause these
defects. In separate experiments, we have observed that
upregulation of the chymotryptic-like activity occurs in the
acute phase of high glucose (3–5 days) (M.A. Queisser,
unpublished data), suggesting that hyperglycemia affects
the proteasomal activity in a biphasic manner. These
observations may explain the apparent discrepancies re-
ported in the literature. Interestingly, stimulation with only
reactive carbonyl compounds affected the chymotrypsin-
like activity. However, this treatment was sufﬁcient to
cause accumulation of ubiquitinated proteins. This is
consistent with data indicating that the chymotrypsin-like
activity is the proteolysis rate-limiting function (32).
The 26S proteasome with the ubiquitin/ATP-dependent
19S complex is more sensitive to oxidative stress than the
ubiquitin/ATP-independent 20S core complex. However,
mildly oxidized proteins are rapidly degraded by the 20S
proteasome, which does not require assembly with the 19S
complex. Here, high glucose also led to downregulation of
the proteasomal 19S regulatory complex, suggesting that
the ubiquitin-proteasome system may initially respond to
increased oxidative stress by increasing the 20S protea-
some and thus facilitating the degradation of oxidized and
aggregated proteins as an early event under hyperglycemic
conditions. More chronically, however, this reduction of
the ubiquitin/ATP-dependent 19S complex may cause ac-
cumulation of polyubiquitinated intracellular proteins.
Previously, it was reported that protein glycation has an
inhibitory effect on protein ubiquitination because for
both, modiﬁcations occur on epsilon-amino groups in
lysine residues (33). However, the major intracellular AGE
precursor is MGO, which, along with its analog glyoxal,
preferentially modiﬁes arginine residues. Consistent with
this, ubiquitinated AGEs were immunoprecipitated from
glyoxal-treated ﬁbroblasts, although it is not clear whether
glycated proteins were mono- or polyubiquitinated (34).
To evaluate the effects of diabetic hyperglycemia and
increased intracellular MGO in vivo, we used three mouse
models.
In insulin-deﬁcient Ins2
Akita mice, which develop hyper-
glycemia soon after weaning (35), proteasomal activity
measurements in aorta conﬁrmed the in vitro ﬁnding that
exclusively the chymotrypsin-activity was reduced,
whereas the trypsin- and caspase-like activities were not
changed. In contrast, no signiﬁcant change in proteasome
activation was noted in heart tissue, indicating that the
cardiac proteasome might have speciﬁc properties for
responding to cellular stress such as hyperglycemia. This
may reﬂect the fact that the cardiac proteasome complex
contains special inducible subunits (36). Surprisingly, the
kidney revealed a highly signiﬁcant decrease in all three
proteasomal activities.
We next examined kidneys from nondiabetic GLO1-
knockdown mice, which exhibited reduced chymotrypsin-
like activity only. This observation indicated that
TABLE 1
20S proteasome modiﬁcation after incubation with MGO in vitro
Subunit Peptide Sequence Modiﬁcation
5 117–123 LLARQCR 7:methylimidazolone
5 124–130 IYELRNK 5:methylimidazolone
2 30–41 DDHDKMFKMSEK 8:carboxyethyllysine
2 69–85 MRNGYELSPTAAANFTR 17:methylimidazolone
4 217–227 CMRVLYYRDAR 8:arg-pyrimidin
4 220–231 VLYYRDARSYNR 5:methylimidazolone
4 225–240 DARSYNRFQIATVTEK 7:methylimidazolone
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FIG. 5. Decreased proteasomal activity in organs from diabetic Ins2
Akita mice. Proteasomal activity and proteasome expression was determined
in kidney, heart, and aorta from diabetic Ins2
Akita mice (n  6) and control wild-type mice (n  6). The three proteolytic activities of the
proteasome were measured with ﬂuorogenic substrates. Trypsin-like (A) and caspase-like (B) activities were signiﬁcantly reduced in kidneys
from diabetic mice. The chymotrypsin-like activity (C) was signiﬁcantly reduced in kidney and aorta, whereas in the heart no signiﬁcant changes
were seen. The 20S proteasome protein levels were not signiﬁcantly changed in any organs, as shown by Western blotting (D and E). Data
represent means  SD from at least three separate experiments. *P < 0.05.
M.A. QUEISSER AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 675increased MGO in the absence of hyperglycemia was
sufﬁcient to induce decreased proteasome function. STZ
diabetes, a chemical model of type 1 diabetes, also showed
reduced chymotrysin-like activity. In both models, MGO
modiﬁcation of the 20S proteasome subunit was detected.
Both of these changes were increased further in STZ
diabetic/GLO1- knockdown mice. Both nondiabetic GLO1-
knockdown and STZ diabetic mice showed decreased
chymotrypsin-like activity only, while Akita mice exhib-
ited reductions in all three proteasomal activities in the
kidney. This may reﬂect the fact that Ins2
Akita mice, in
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KD), and STZ diabetic and GLO1-knockdown diabetic (GLO1-KD-STZ)
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ited a signiﬁcant increase in MGO- and ubiquitin-modiﬁed proteins in
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were scanned and quantiﬁed using the Odyssey imaging system. Data
are expressed as means  SD. *P < 0.05 vs. wild type; n  4. RFU,
relative ﬂuorescence unit. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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2-subunit was detected in kidneys from GLO1-knockdown and STZ
diabetic mice (B). The protein band densities were scanned and
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immune complex-mediated pathology. Genetic back-
ground differences between the strains may also be
important.
Collectively, these results show that reactive carbonyl
compounds selectively inhibited the chymotrypsin-like
activity of the proteasome in cell culture and in vivo.
Although it was previously described that glyoxal inhibited
all three proteasomal activities (34), the ﬁndings documented
here are consistent with other reports observing that chem-
ical compounds selectively target the chymotrypsin-like
activity of the proteasome (37,38). In addition to decreas-
ing chymotrypsin-like activity in the 20S proteasome, we
found that increased intracellular MGO caused a marked
decrease in protein levels of the regulatory 19S component
of the 26S proteasome. Previously, Zhang et al. (39) de-
scribed that the O-linked N-acetylglucosamine (O-GlcNAc)
transferase was able to modify the 19S regulatory subunit
of the proteasome. The Rpt2 ATPase (19S-S4) in the
mammalian proteasome 19S cap is modiﬁed by O-GlcNAc
in vitro and in vivo, and as its modiﬁcation increases, 26S
proteasome function decreases. Since hyperglycemia in-
creases intracellular protein modiﬁcation by O-GlcNAc
(10), this change in diabetic tissues would further augment
the inhibitory action of hyperglycemia on proteasome
function. The relationship between increased MGO and
increased O-GlcNAc modiﬁcation remains to be clariﬁed.
However, O-GlcNAc modiﬁcation of 19S-S5a was in-
creased in kidneys of nondiabetic GLO1-knockdown mice,
suggesting that MGO increases this modiﬁcation (D. Yao,
unpublished data).
Based on the presented data and previous publications,
we propose the following mechanism: Chronic high glu-
cose causes increased intracellular reactive oxygen spe-
cies in cells that cannot downregulate glucose transport.
This intracellular hyperglycemia increases MGO concen-
tration in microvascular endothelial cells in retina and
kidney with the formation and accumulation of reactive
carbonyl compounds. MGO covalently modiﬁes 20S pro-
teasome subunits, which decreases the proteasomal
chymotrypsin-like activity. In addition, increased MGO re-
duces 19S protein levels. Decreased levels of the poly-
ubiquitin receptor 19S-S5a cause polyubiquitinated pro-
teins to accumulate in the cell, which may interfere with
the function of their nonubiquitinated counterparts. The
decrease of the proteolysis rate-limiting step may inﬂu-
ence other proteasomal activities, the decline of which
over time was detected in kidney from Ins2
Akita mice.
However, the precise contribution of impaired proteasome
function to the functional and structural changes of dia-
betic nephropathy remains to be elucidated.
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